Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 5, 2010, Pages 1296-1302

  Albert, Jeffrey M ^a   Gonzalez Angulo, Ana M ^a   Guray, Merih ^a   Sahin, Aysegul ^a   Strom, Eric A ^a   Tereffe, Welela ^a   Woodward, Wendy A ^a   Tucker, Susan L ^a   Hunt, Kelly K ^a   Hortobagyi, Gabriel N ^a   Buchholz, Thomas A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ER; estrogen receptor; HER2; local recurrence; locoregional recurrence; PR; progesterone receptor

Indexed keywords

ER; ESTROGEN RECEPTOR; HER2; LOCAL RECURRENCE; LOCOREGIONAL RECURRENCE; PR; PROGESTERONE RECEPTOR;

MONOCLONAL ANTIBODIES; MULTIVARIANT ANALYSIS; PESTICIDE EFFECTS; TUMORS;

CHEMOTHERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; CONSERVATIVE TREATMENT; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ANALYSIS OF VARIANCE; BREAST TUMOR; CHEMISTRY; FEMALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SEGMENTAL MASTECTOMY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 77955504676     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.12.011     Document Type: Article

References (31)

1. F.J. Esteva, and G.N. Hortobagyi Prognostic molecular markers in early breast cancer Breast Cancer Res 6 2004 109 118
2. S.J. Payne, R.L. Bowen, and J.L. Jones Predictive markers in breast cancer - The present Histopathology 52 2008 82 90
3. V.R. Grann, A.B. Troxel, and N.J. Zojwalla Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma Cancer 103 2005 2241 2251
4. D.J. Slamon, G.M. Clark, and S.G. Wong Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
5. S. Paik, R. Hazan, and E.R. Fisher Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer J Clin Oncol 8 1990 103 112
6. M.F. Press, L. Bernstein, and P.A. Thomas HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas J Clin Oncol 15 1997 2894 2904
7. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials Lancet 365 2005 1687 1717
8. P.L. Bedard, and M.J. Piccart-Gebhart Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer Clin Breast Cancer 8 Suppl. 4 2008 S157 S165
9. P.C. Roche, V.J. Suman, and R.B. Jenkins Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831 J Natl Cancer Inst 94 2002 855 857
10. S. Paik, J. Bryant, and E. Tan-Chiu Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience J Natl Cancer Inst 94 2002 852 854
11. A.M. Gown Current issues in ER and HER2 testing by IHC in breast cancer Mod Pathol 21 Suppl. 2 2008 S8 S15
12. J.R. Benson, I. Jatoi, and M. Keisch Early breast cancer Lancet 373 2009 1463 1479
13. National Comprehensive Cancer Network. National Comprehensive Cancer Network clinical practice guidelines in oncology: Breast cancer. 2009; v.1.2009. http://www.nccn.org, accessed Oct 1, 2009.
14. H. Joensuu, P.L. Kellokumpu-Lehtinen, and P. Bono Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 2006 809 820
15. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
16. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
17. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC,T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC,TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [Abstract]. San Antonio Breast Cancer Symposium, 2006.
18. Rakkhit R, Broglio K, Peintinger F, et al. Significant increased recurrence rates among breast cancer patients with HER2-positive tumors 1 cm or smaller [Abstract]. San Antonio Breast Cancer Symposium, 2008.
19. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 547 581
20. D.R. Cox, and N. Oakes Analysis of survival data 1988 Chapman and Hall New York
21. B.G. Haffty, F. Brown, and D. Carter Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study Int J Radiat Oncol Biol Phys 35 1996 751 757
22. E.E. Harris, W.T. Hwang, and E.A. Lee The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy Breast J 12 2006 431 436
23. W.A. Woodward, E.A. Strom, and S.L. Tucker Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation Int J Radiat Oncol Biol Phys 57 2003 336 344
24. B. Fisher, J. Dignam, and E. Tan-Chiu Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes J Natl Cancer Inst 93 2001 112 120
25. P.L. Nguyen, A.G. Taghian, and M.S. Katz Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy J Clin Oncol 26 2008 2373 2378
26. R.J. Pietras, J.C. Poen, and D. Gallardo Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene Cancer Res 59 1999 1347 1355
27. G.S. Rao, S. Murray, and S.P. Ethier Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor Int J Radiat Oncol Biol Phys 48 2000 1519 1528
28. T.A. Buchholz, E.H. Huang, and D. Berry Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy Int J Radiat Oncol Biol Phys 59 2004 1337 1342
29. S. Paik, J. Bryant, and C. Park erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst 90 1998 1361 1370
30. A. Moliterni, S. Menard, and P. Valagussa HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer J Clin Oncol 21 2003 458 462
31. F. Zhang, Y. Yang, and T. Smith Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma Cancer 97 2003 1758 1765